Objectives. Immunosuppressive therapy is necessary to alter the natural course of SLE. However, immunosuppressant-related cancer risk is a major concern. The aim of this study was to determine whether immunosuppressant use is associated with cancer risk in SLE.
Introduction
SLE is an autoimmune rheumatic disease affecting multiple systems and organs. It develops mainly in young females, and is associated with a wide range of manifestations. Immunosuppressive or cytotoxic agents including HCQ, AZA, CYC, MTX and mycophenolate are often used in combination with systemic glucocorticoid therapy to treat patients with refractory symptoms or major organ involvement [1, 2] . The overall survival in SLE has significantly increased in past decades [3] , but morbidity, such as cancers, still affects long-term outcomes dramatically. A recent meta-analysis showed an increased risk of haematological and non-haematological cancers in SLE [4] .
The reason for the association between SLE and cancer is still unclear. Known cancer risk factors in patients with SLE include older age, tobacco exposure and lupusrelated organ damage [5] . Regarding immunosuppressant use, conflicting opinions have been expressed in various studies. Bernatsky and colleagues [5, 6] indicated that immunosuppressive therapy, especially when including CYC, may contribute to haematological cancers. However, in the study by Lofstrom et al. [7] this drug was not one of the factors responsible for the increased risk. It is difficult to associate cancer risks with the use of immunosuppressants among patients with SLE for the following reasons: cofounding factors, such as disease activity [8] cannot be eliminated in patients with SLE; and cancer incidence in patients with SLE is too low for reliable statistical analysis.
Patients with SLE are also at an increased risk of cancers in Taiwan [9, 10] . One research group suggested that another survey is needed to obtain results on the relation between immunosuppressants and cancer incidence among patients with SLE. Therefore, we designed a nested casecontrol study to determine whether the use of traditional immunosuppressants, such as AZA, CYC, MTX, HCQ and systemic glucocorticoids, affects the overall risk of cancer in Taiwan.
Methods

Study design
This study was designed as a retrospective event risk analytical cohort study. We enrolled consecutive patients with SLE from Taiwan's National Health Insurance Research Database (NHIRD) from 1 January 2001 to 31 December 2013. We subdivided the study subjects into a cancer group and control group. We recorded the total dose (milligram) of the immunosuppressants of interest, which were AZA, CYC, MTX, HCQ and systemic glucocorticoids since the day of SLE diagnosis to cancer occurrence in the cancer group or a matched end of follow-up in the control group.
To protect patient privacy, NHIRD has used numbers and letters from the English alphabet as identifying codes to replace name and ID number. Because all data linked to ID was removed, the researcher cannot identify individual data from NHIRD, and therefore informed patient consent was not necessary in the study. The study was approved by the Chang Gung Medical Foundation Institutional Review Board, No. 201600219B1.
Brief background on Taiwan's National Health Insurance and NHIRD Taiwan's National Health Insurance (NHI) is a governmentrun, single-payer NHI scheme, which currently enrols >96% of Taiwan's population [11, 12] . When individuals enrol in the NHI programme, they have to apply for an NHI Card, which is a personal health passport. Taiwan's NHI utilizes a comprehensive computerized and internetbased system. Whenever patients visit a doctor, pick up medicine or have a test performed, they can use their NHI card to obtain treatment under the NHI programme [13] .
NHIRD contains healthcare information on 23 million people in Taiwan If a specialist diagnosed a patient as having SLE (International Classification of Diseases (ICD)-9: 710.0), a condition classified as a catastrophic illness by the Ministry of Health and Welfare of Taiwan, the specialist can apply for a catastrophic illness certificate for the patient [13] . A comprehensive application document and relevant information, including a detailed medical record, laboratory data, imaging report or pathological study should be submitted to the NHI Administration. The application will be formally reviewed anonymously by another senior and experienced rheumatologist assigned by the NHI Administration. The review is performed according to the 1997 ACR criteria in which four or more of the manifestations must be present [14] . If approved, the certificate of the patient's catastrophic illness is directly entered into the patient's NHI Card. Otherwise, the application will be rejected. The review process is considerably strict because patients with catastrophic illness certification who obtain care for the illness or related conditions within the certificate's validity period do not need to make a co-payment for outpatient or inpatient care. All individuals with a catastrophic illness certificate will be enrolled into the Database for Registration of Patients with a Catastrophic Illness (DRPCI), a sub-dataset of NHIRD. The SLE subjects in the current study were retrieved from the DRPCI following the method used in previous studies [9, 15] .
We tried to avoid competing risks, such as mortality; therefore, the following exclusion criteria were used: patients with a cancer diagnosis before enrolment; and mortality due to any cause except cancer during the follow-up period.
Outcome identification and exposure to medication of interest We identified cancer diagnosis explanations in the DRPCI. The criteria for a confirmed cancer diagnosis in the Taiwan DRPCI were: tissue proof (a histopathological or cytological examination and imaging study that validated the cancer diagnosis); and a second opinion of an oncologist. The classification of cancers was according to ICD-9 codes from 140 to 208.91.
For the five medications of interest, the cumulative period for the doses was from the day of SLE diagnosis to the day of cancer diagnosis in the cancer group. In the matched control group, this period was from the day of SLE diagnosis to the day of the matched end of follow-up. These medications were fully reimbursed in the NHI programme. All prescriptions were recorded, in both outpatient visits and inpatient therapy.
Definitions of comorbidities
For chronic diseases, such as hypertension, diabetes mellitus, dyslipidaemia, cirrhosis, peptic ulcers and chronic obstructive pulmonary disease, there had to be two records of an outpatient principal diagnosis or one admitted diagnosis 1 year before the start of the study period (index date). Non-immunosuppressant drugs, including systemic NSAIDs, selective cyclooxygenase 2 inhibitors (celecoxib and etoricoxib) and aspirin, had to be prescribed at least once in the follow-up period. Overlapping immune diseases, including RA and SS, were defined as the presence of the relevant ICD numbers at least twice after the index date. RA and SS are the two most common autoimmune rheumatic diseases in Taiwan [16, 17] and are possibly associated with cancer [18, 19] .
Propensity score matching
We performed propensity score matching to minimize the selection bias when evaluating the effect of the immunosuppressant dose on the risk of cancer. We matched each subject with cancer (the cases) with four subjects without cancer (the controls) using the propensity score. We calculated the propensity score using the following covariates: age at SLE diagnosis, gender, six comorbidities (hypertension, diabetes mellitus, dyslipidaemia, cirrhosis, peptic ulcers and chronic obstructive pulmonary disease), use of non-immunosuppressant drugs during the followup, the annual number of admissions because of SLE during the follow-up, overlapping immune diseases (i.e. SS and RA) during the follow-up and the follow-up duration. Each patient with cancer was followed up from the date of SLE diagnosis until the date of cancer diagnosis, whereas the patients in the control group were followed up from the date of SLE diagnosis until the last date of the database (31 December 2013). We excluded the patients in the control group who died during the follow-up.
Statistical analysis
We compared the patient characteristics between the case and control groups using an independent-sample t test for continuous variables or the chi-square test for categorical variables. Because of the nature of the retrospective nested casecontrol study, conditional logistic regression analysis is required when analysing the association between the risk of cancer and an immunosuppressant dose [20] . The total dose of each immunosuppressant during the follow-up was obtained by summation and was treated as an independent variable in the logistic models. The immunosuppressant dose was log-transformed before introducing it into the logistic model because of its non-normal distribution and overdispersion. To evaluate the dose-dependent effect of the immunosuppressant dose on the risk of cancer, we stratified patients into several groups by their total dose and performed a test of linear contrast in the logistic model. In the aforementioned logistic models, we first tested the associations without considering possible confounding variables (as a univariate analysis), and we then further tested the associations with adjustment of all the variables listed in Table 1 except for follow-up years (as a multivariable analysis). The data analysis and propensity score matching were conducted using SAS software version 9.3 (SAS Institute, Cary, NC, USA).
Results
Patient characteristics
A total of 14 842 patients with a diagnosis of SLE with a catastrophic illness certificate between 1 January 2001 and 31 December 2013 were identified. We excluded 191 patients who received a diagnosis of cancer before an SLE diagnosis and 1531 subjects in the control group who died during the follow-up. There were 13 120 patients, including 444 cancer patients (3.4%) and 12 676 cancer-free patients, eligible for analysis. After matching each cancer case with four cancer-free control patients, the present study consisted of 330 cancer patients and 1320 matched cancer-free patients (Fig. 1) . Table 1 lists the patient characteristics before and after propensity-score matching. Before matching (left panel in Table 1 ), patients in the case group were older, were more likely to be male, had a higher prevalence of comorbidities (e.g. dyslipidaemia or liver cirrhosis), were less likely to be prescribed NSAIDs, were more likely to be hospitalized due to SLE during the follow-up, and had a shorter follow-up duration than did the patients in the control group. We found that the distribution of patient characteristics was well balanced between the case and control groups after matching (right panel in Table 1 ).
All cancers and specific cancer types Table 2 shows all types of cancers, mainly haematological (11.7%) and non-haematological (88.3%). The most frequently observed type of cancer was breast cancer (16.9%), followed by haematological (11.7%, including leukaemia and non-Hodgkin's lymphoma), colorectal (11.0%), lung (10.6%) and hepatobiliary cancers (10.4%). None of the patients in this cohort had Hodgkin's lymphoma.
Exposure to an immunosuppressant and the risk of cancer Table 3 summarizes the results of the correlation analysis of the cumulative immunosuppressant dose (exposure) and the risk of cancer. The univariate analysis revealed that a higher cumulative CYC dose was associated with a higher risk of cancer (OR = 1.09, 95% CI: 1.05, 1. Table 1 .
We further subdivided the patients into three groups (low-dose group, 0 mg; medium-dose group, <2000 mg; and high-dose group, 52000 mg) by the total CYC dose. A significant-trend test indicated that a higher cumulative CYC dose correlated with an increased risk of cancer in a dose-dependent manner (P < 0.001 in both the univariate and multivariable analyses; Fig. 2) .
Likewise, patients were classified into three groups (low-dose group, 0 mg; medium-dose group, <20 000 mg; and high-dose group, 520 000 mg) by their total HCQ dose. We used the cut-off point for the cumulative HCQ dose of 20 000 mg (200 mg/day for 100 days) based on the design of previous studies on the use of HCQ daily for at least 3 or 4 months to evaluate its effect [21, 22] . The results revealed that a higher cumulative HCQ dose was associated with a decreased risk of cancer in a dose-dependent manner (P = 0.004 in the univariate analysis; P = 0.003 in the multivariable analysis; Fig. 3 ).
Discussion
To our knowledge, only a few studies have examined the association between cancer and immunosuppressant use among patients with SLE, indicating a possible higher cancer risk with immunosuppressant use [5, 6, 23] . The In our study, a higher cumulative cyclophosphamide dose was associated with an increased risk of cancer. For other immunosuppressants, including systemic glucocorticoids, the percentage utilization and dose in the cancer group were similar to (or lower than) those in the control group (Table 3 ). This finding implies that these cancer patients did not have a higher SLE disease activity in this study. Bernatsky et al. [6] indicated a higher lymphoma risk among patients treated with CYC. Disease activity was not associated with lymphoma risk in their study. Nevertheless, CYC can be effective in the treatment of major SLE involvement. Rheumatologists did not always have an option for the treatment of major organ involvement in SLE in the past.
Our findings do not clearly prove that CYC exposure drives cancer development in SLE. In fact, 70% of the patients with cancer were not exposed to CYC before the cancer developed. Some hypotheses regarding the association of CYC with a higher incidence of cancer have been proposed but are still unproven. First, CYC is electrophilic and may cause DNA damage via the formation of DNA adducts [24] . Second, the observed relation may be linked to immunosuppression, cytotoxicity or the emergence of an oncogenic virus (e.g. HPV) [25] . Finally, genetic factors related to drug metabolism, such as cytochrome P450 [26] and glutathione S-transferase polymorphisms [27] may play a role in the individual differences in adverse drug effects.
HCQ is the most widely used antimalarial agent for lupus treatment [28] . In addition to its outstanding effects on skin and joint symptoms, several lupus studies have identified many other beneficial effects of HCQ on various parameters, including survival [29] and accrual of organ damage [30] . Ruiz-Irastorza et al. [31] proposed a hypothesis of a protective action of antimalarial agents against cancer among patients with SLE. Our larger-scale study also found an inverse relationship between HCQ and cancer and further evaluated the concept of a cumulative dose effect, though analysis of different ethnic cohorts might be necessary.
Some studies mention the potential influence of antimalarials on cancer. First, the antimalarial drug could activate ataxia telangiectasia mutated signalling to help the repair of the DNA breaks [32] . Second, chloroquine increases the synthesis of p53, which protects DNA from genotoxic insults [33] . Third, HCQ could trigger lysosome-initiated cell death and apoptosis [34] . Finally, antimalarial drugs are strong DNA-intercalating agents and inhibit the limitless replicative potential of tumour cells [35] .
In the present study, we also found that the CYCrelated cancer risk was dependent on the cumulative dose (Fig. 2) . There is a risk of cancer even with a low dose, and it gradually increases with the cumulative dose. Therefore, caution is advised even with low doses of cyclophosphamide. On the other hand, this is the first study to show that HCQ might reduce the risk of cancer in a dose-dependent manner among patients with SLE (Fig. 3) . Recent data also indicated that HCQ reduces the incident diabetes mellitus risk in SLE in a dose-dependent manner [36] . The cumulative dose of HCQ might also affect other parameters, but further studies are needed to clarify this. Because of its many other benefits, we recommend the long-term use of HCQ for all SLE patients.
As for AZA, MTX and systemic glucocorticoids (see Supplementary Fig. S1 , available at Rheumatology Online), they were found to have no obvious effect on cancer development in patients with SLE (Table 3) . However, an elevated cancer risk associated with MTX and AZA in patients with RA was found in previous studies [37, 38] , which may be due to long-term use. For SLE patients, however, these drugs are prescribed for a relatively short period, especially during a disease flareup. In addition, there may be inconsistent organ involvement and different indications for the prescription of the drugs in the two diseases. Differences in treatment schedules and pathogenesis between RA and SLE may be responsible for these discrepant findings.
In our SLE cohort, the top five types of cancers were breast, haematological, colorectal, lung and hepatobiliary cancers. Compared with the general population, haematological cancers, especially non-Hodgkin's lymphoma, had a relatively high prevalence in our cohort. Several factors, including uncontrolled lymphocyte activation [8] , defective apoptosis [39] and EBV infection [40] , have been proposed to explain this association.
There are some limitations of this study. First, 'confounding by indications' is almost impossible to avoid in a retrospective cohort study, especially in a study using an insurance database. For instance, patients with more severe manifestations may be treated with stronger immune modulators and not HCQ [41] . However, an extensive effort was made through the use of propensity score matching to minimize the threat of 'confounding by indications'. Because individual laboratory data were not available, disease activity could not be evaluated using SLEDAI [6] or SLICC/ACR damage [5] scores as in other studies. Therefore, the associations among cancer, drug exposure and disease-related factors in SLE are difficult to identify. According to the report by Lee et al. [42] , the frequency of admissions may be associated with the undulating SLE disease activity index, so we used annual hospitalization numbers to assess lupus activity. In addition to the general variables, such as age, gender, comorbidities, drugs, overlapping immune diseases and follow-up duration, we also matched by the annual hospitalization number to eliminate cofounding factors as much as possible. Second, newer immunosuppressants, such as mycophenolate, ciclosporin and rituximab, were not paid for-as an SLE treatment-in Taiwan's NHI. Whether the subjects took these medications on a self-paid basis is not noted in the database. Therefore, our study could not provide information on the new immunosuppressants. Additional detailed analyses of SLE in medical charts may be necessary in the future.
Third, when surveying the absolute cumulative dose effect of several different immunosuppressants instead of the ever/never used status, we did not perform a lag analysis in the current study. Because the association between medication and cancer was still uncertain, there was no known consistent exposure lag. Nonetheless, without the lag, our results on cyclophosphamide are similar to the findings of Bernatsky et al. [6] for a 5-year lag.
In conclusion, a higher cumulative CYC dose appears to contribute to cancer risk, but there is likely a protective dose-dependent effect of HCQ. Rheumatologists can use this new perspective regarding different cancer risks to aid in the selection of medications to treat SLE disease activity and for long-term care.
